2026 ASH®
Annual Meeting & Exposition December 12-15, 2026 ▪ New Orleans, Louisiana

Paper Details

Abstracts, authors, affiliations, and disclosures.

SESSION

655. Multiple Myeloma: Cellular Therapies: Poster II

Program: Poster Abstract Session
Sunday, December 13, 2026
06:00 p.m. - 08:00 p.m.
MCCNO - Hall F
Access, Representation, Population Health, Technology and Procedures, Omics Technologies, Treatment Considerations, Combination Therapy, Supportive Care, Therapy Sequence, Biological Therapies, Bispecific Antibody Therapy, (CAR)-T Cell Therapies, Immunotherapy, Adverse Events, Artificial Intelligence (AI), Biological Processes, Immune Mechanism, Clinical Practice (Health Services and Quality), Patient Safety, Quality of Care, Diseases, Infectious Diseases, Lymphoid Malignancies, Plasma Cell Disorders, Myeloid Malignancies, Measurable Residual Disease, Research, Translational Research, Clinical Research, Clinical Trials, Epidemiology, Health Outcomes Research, Real-World Evidence, Registries, Study Population, Human, Adult
PAPER

4042 Matching-adjusted indirect comparisons (MAICs) of anitocabtagene autoleucel (anito-cel) vs teclistamab and talquetamab for the treatment of 4L+ relapsed and/or refractory multiple myeloma (RRMM): Analysis with extended iMMagine-1 follow-up

Krina Patel Jr, MD, MSc, Vania Hungria, MD, PhD2, Ken Hasegawa, PhD3, Brett Doble4, Julia Thornton Snider, PhD5, Monique Giordana, PharmD6, Ke Zhang, PhD7, Steve Kanters, PhD8, Surbhi Sidana, MD9, Philippe Moreau Sr, MD, PhD10
1 The University of Texas MD Anderson Cancer Center, Houston, Texas, United States
2 Clínica Médica São Germano, São Paulo, Brazil
3 Kite Pharma, a Gilead Company, Santa Monica, California, United States
4 Kite Pharma, a Gilead Company, Santa Monica, California, United States
5 Kite Pharma, a Gilead Company, Santa Monica, California, United States
6 Kite Pharma, a Gilead Company, Santa Monica, California, United States
7 RainCity Analytics Inc, Vancouver, British Columbia, Canada
8 RainCity Analytics Inc, Vancouver, British Columbia, Canada
9 Stanford School of Medicine, Palo Alto, California, United States
10 Hôtel-Dieu, Nantes, France

Introduction: Mature time-to-event (TTE) and safety comparisons of anito-cel (iMMagine-1) vs bispecific antibodies (BsAbs) using longest available follow-up are lacking. MAICs evaluated anito-cel against teclistamab (TEC; MajesTEC-1) and talquetamab (TAL; MonumenTAL-1), the earliest approved and most widely used BCMA- and GPRC5D-targeting BsAb therapies, respectively.

Methods: Unanchored MAICs, per a pre-specified statistical analysis plan, used individual patient-level data from iMMagine-1 (efficacy evaluable population; N=117) at 18-month median follow-up (mFU), and aggregate data from MajesTEC-1 (N=165; mFU=14.1m), MonumenTAL-1 (TAL 0.4mg: N=143 with mFU=18.8m; TAL 0.8mg: N=145 with mFU=12.7m or N=154 with mFU=19.4m). Anito-cel was given as a single infusion, while TEC once weekly (QW), TAL 0.4mg QW and 0.8mg Q2W were given until disease progression. iMMagine-1 patients were reweighted using key prognostic factors identified by systematic review and physician consultation: extramedullary disease, cytogenetic risk, refractory status, international staging system (revised if available), and % bone marrow plasma cells (BMPC) for efficacy; and ECOG, % BMPC, age, and sex for safety. Sensitivity analyses used the iMMagine-1 enrolled population (N=129) and additional prognostic factors. Relative effects for TTE outcomes were described using hazard ratios (HR) if the proportional hazards assumption was met or using restricted mean survival time (RMST) differences at 24 months otherwise (positive: favor anito-cel), and odds ratios (OR) for response and safety.

Results: Between-trial baseline characteristics were similar, with balanced weights and effective sample sizes of 89–111 for TEC and 47–112 for TAL.

Following MAIC adjustments, anito-cel showed significantly higher response rates vs both BsAbs. For overall response rate, anito-cel had an OR of 8.67 (95% confidence interval [CI]: 2.86-26.25), 4.12 (95% CI: 1.22-13.95), and 4.08 (95% CI: 1.32-12.59), vs TEC, TAL 0.4mg, and TAL 0.8mg, respectively. Benefits extended to deeper responses. Odds of ≥CR were higher for anito-cel vs TEC (OR: 3.81; 95% CI: 2.14-6.78), TAL 0.4mg (OR: 4.46; 95% CI: 2.40-8.30), and TAL 0.8mg (OR: 3.45; 95% CI: 1.72-6.94), and odds of ≥VGPR were higher for anito-cel vs TEC (OR: 4.30; 95% CI: 2.08-8.88), TAL 0.4mg (OR: 3.43; 95% CI: 1.58-7.45), and TAL 0.8mg (OR: 3.18; 95% CI: 1.37-7.35). Overall minimal residual disease (MRD) negativity at 10-5 and ≥CR with MRD negativity were also significantly improved.

Similarly, compared with TEC, anito-cel significantly improved progression-free-survival (PFS; RMST: 6.15; 95% CI: 4.05-8.25) and overall survival (OS; HR: 0.22; 95% CI: 0.11-0.42). No significant difference in duration of response (DOR; HR: 0.84; 95% CI: 0.53-1.31) was observed. Compared with TAL, findings varied by dose. Relative to TAL 0.4mg, anito-cel had improved PFS (RMST: 7.51; 95% CI: 5.37-9.65), OS (HR: 0.37; 95% CI: 0.18-0.74), and DOR (HR: 0.43; 95% CI: 0.28-0.65). For TAL 0.8mg, anito-cel showed a significant PFS benefit (RMST: 5.48; 95% CI: 3.06-7.89), however, it did not significantly differ with respect to OS (HR: 0.58; 95% CI: 0.28-1.21) and DOR (HR: 0.61; 95% CI: 0.35-1.06).

For safety, grade ≥3 CRS and ICANS did not differ significantly for anito-cel vs TEC or anito-cel vs TAL; nor did any grade CRS vs TAL 0.4mg, or any grade ICANS vs TEC. However, anito-cel was differentiated from comparators in some other key outcomes. Anito-cel had significantly lower odds of any grade ICANS relative to TAL 0.4mg (OR: 0.15; 95% CI: 0.07-0.34) and TAL 0.8mg (OR: 0.24; 95% CI: 0.11-0.53). Additionally, anito-cel was associated with significantly lower odds of grade 3-4 infections vs TEC (OR: 0.08; 95% CI: 0.04-0.16), TAL 0.4mg (OR: 0.36; 95% CI: 0.16-0.82), and TAL 0.8mg (OR: 0.38; 95% CI: 0.17-0.82), and of non-relapse mortality (NRM) vs TEC (OR: 0.23; 95% CI: 0.08-0.63) and TAL 0.4mg (OR: 0.28; 95% CI: 0.09-0.84).

Conclusions: Anito-cel showed a superior efficacy profile vs TEC and TAL across most efficacy outcomes, alongside a differentiated safety profile characterized by lower odds of any grade ICANS vs TAL, and high-grade infections/NRM across all comparators. The increased infection risk of BsAbs may be related to the continuous administration required to maintain treatment response. These findings support a clinically meaningful benefit-risk advantage of single-infusion anito-cel vs BCMA- and GPRC5D-targeting BsAbs in 4L+ RRMM.

Krina Patel Jr, MD, MSc: Janssen, Legend Biotech, AstraZeneca, AbbVie, Regeneron, Merck, Genentech, Takeda, Caribou Biosciences, and Pfizer - Honoraria; JnJ/Janssen - Honoraria; Bristol Myers Squibb - Honoraria; Bristol Myers Squibb - Research Funding; Takeda - Research Funding; Celgene/BMS - Research Funding; Kite, a Gilead Company - Research Funding; Nektar and Allogene - Research Funding; Sanofi - Research Funding; Bristol Myers Squibb - Research Funding; Indapta - Research Funding; JnJ/Janssen - Research Funding; AbbVie - Consultancy (Includes expert testimony); Oricell - Consultancy (Includes expert testimony); AstraZeneca - Consultancy (Includes expert testimony); Johnson & Johnson - Consultancy (Includes expert testimony); Kite, a Gilead Company and Novartis - Consultancy (Includes expert testimony); Legend Biotech - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Janssen, Legend Biotech, AstraZeneca, AbbVie, Regeneron, Merck, Genentech, Takeda, Caribou Biosciences, and Pfizer - Consultancy (Includes expert testimony); Pfizer - Consultancy (Includes expert testimony); Takeda - Consultancy (Includes expert testimony); Poseida - Consultancy (Includes expert testimony); Eli Lilly - Consultancy (Includes expert testimony); Kite, a Gilead Company - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Bristol Myers Squibb - Consultancy (Includes expert testimony); Celgene/BMS - Consultancy (Includes expert testimony); JnJ/Janssen - Consultancy (Includes expert testimony); Novartis - Consultancy (Includes expert testimony); Sanofi - Consultancy (Includes expert testimony); Genentech - Consultancy (Includes expert testimony); Regeneron - Consultancy (Includes expert testimony); Celgene/BMS - Membership on a Board/Advisory Committee